ClinicalTrials.gg
CompletedNCT00129116Updated Aug 27, 2018Results posted

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

A Phase 2 interventional study of Hib-MenCY-TT vaccine and Hib-MenC-TT vaccine in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 26 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-27.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
47th of 80
388 · median 445
Started
2003
with 6 others
Phase 2
22 of 82
none open now
Registered
2nd of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 47th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2003, is one of 22 in phase 2, and was the 2nd registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine and 1 formulation of Hib-MenC-TT vaccine compared to a control group receiving licensed meningococcal serogroup C conjugate vaccine, each administered at 2, 3, and 4 months of age. Antibody persistence and immune responses to booster vaccinations were additionally assessed at 12 to 18 months of age.

Read the detailed description

Primary \& booster vaccination study to evaluate the immuno,reacto \& safety of 3 diff. formulations of GSKBio'combined Haemophilus influenzae typeb-meningococcal serogroups C \& Y-conjugate vaccine \& one formulation of GSKBio' Haemophilus influenzae typeb-meningococcal serogroup C conjugate vaccine each given concomitantly With Infanrix penta (DTaP-IPV-HepB vaccine), vs Meningitec meningococcal SerogroupC conj.vaccine) given concomitantly With Infanrix hexa (DTaP-IPV-HepB-Hib vaccine) in infants according a 2-3-4 mth schedule

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Keywords

  • Invasive bacterial disease caused by Hib
  • Neisseria meningitidis serogroups C & Y
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants without major congenital illness, , or chronic disease born at 36 to 42 weeks of gestation, between 6 and 12 weeks of age at enrollment, and vaccinated against at birth.

Exclusion criteria

Exclusion Criteria:

  • Infants should not have received any drug, vaccine, chronic , or immunoglobulin or blood products.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Menhibrix F1/Infanrix-penta Group

    Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.

    Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®

  • Experimental
    Menhibrix F2/Infanrix-penta Group

    Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.

    Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®

  • Experimental
    Menhibrix F3/Infanrix-penta Group

    Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.

    Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®

  • Experimental
    Menitorix/Infanrix-penta Group

    Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.

    Biological: Hib-MenC-TT vaccine · Biological: Infanrix penta ®

  • Active comparator
    Menjugate/Infanrix-hexa Group

    Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.

    Biological: Menjugate ® · Biological: Infanrix hexa ®

Interventions

  • Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

  • BiologicalHib-MenC-TT vaccine

    Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

  • BiologicalMenjugate ®

    Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

  • Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

    Also known as: DTPa-HBV-IPV vaccine

  • Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

    Also known as: DTPa-HBV-IPV/Hib vaccine

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

    Time frame: One month after dose 3 (at study Month 3 - primary phase)

  2. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

    rSBA-MenC antibody titre cut-off value assessed was ≥1:8

    Time frame: One month after dose 3 (at study Month 3 - primary phase)

  3. Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

    rSBA-MenY antibody titre cut-off value assessed was ≥1:8

    Time frame: One month after dose 3 (at study Month 3 - primary phase)

  4. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

    Time frame: One month after the booster vaccination (at study Month 1 - booster phase)

  5. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

    rSBA-MenC antibody titre cut-off value assessed was ≥1:8

    Time frame: One month after the booster vaccination (at study Month 1 - booster phase)

  6. Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

    rSBA-MenY antibody titre cut-off value assessed was ≥1:8

    Time frame: One month after the booster vaccination (at study Month 1 - booster phase)

Secondary outcomes

  1. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

    rSBA-MenC antibody titre cut-off value assessed was ≥1:8

    Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)

  2. Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

    rSBA-MenY antibody titre cut-off value assessed was ≥1:8

    Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)

  3. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

    Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)

  4. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

    Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)

  5. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

    rSBA-MenC antibody titre cut-off value assessed was ≥1:8

    Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)

  6. Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

    rSBA-MenY antibody titre cut-off value assessed was ≥1:8

    Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)

  7. rSBA-MenC Antibody Titres

    Titres are expressed as geometric mean titres (GMTs)

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  8. rSBA-MenY Antibody Titres

    Titres are expressed as geometric mean titres (GMTs)

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  9. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  10. Anti-PRP Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  11. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

    Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  12. Number of Subjects With Anti-polysaccharide Y (Anti-PSY) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

    Anti-PSY antibody concentration cut-off value assessed was ≥0.30 µg/mL

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  13. Anti-PSC Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  14. Anti-PSY Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  15. Anti-tetanus Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  16. Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN), Anti-pertussis Toxoid (Anti-PT) Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in Enzyme-Linked Immunosorbent Assay (ELISA) Units per millilitre.

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  17. Number of Seroprotected Subjects for Anti-tetanus Antibodies

    Seroprotection status is defined as anti-tetanus toxoid antibody concentration ≥ 0.1 International Units per millilitre (IU/mL)

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  18. Number of Subjects With Anti-FHA, Anti-PRN and Anti-PT Antibody Concentration Equal to or Above 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units Per Millilitre (EL.U/mL)

    Anti-FHA, anti-PRN and anti-PT antibody concentration cut-off value assessed was ≥ 5 ELISA units per millilitre.

    Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)

  19. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).

    Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  20. Anti-PRP Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  21. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:128

    rSBA-MenC antibody titre cut-off value assessed was ≥1:128

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  22. Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:128

    rSBA-MenY antibody titre cut-off value assessed was ≥1:128

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  23. rSBA-MenC Antibody Titres

    Titres are expressed as geometric mean titres (GMTs)

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  24. rSBA-MenY Antibody Titres

    Titres are expressed as geometric mean titres (GMTs)

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  25. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

    Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  26. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 2.0 Microgram Per Millilitre (µg/mL)

    Anti-PSC antibody concentration cut-off value assessed was ≥2.0 µg/mL

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  27. Anti-PSC Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  28. Anti-PSY Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  29. Number of Subjects With Anti-tetanus Toxoid (Anti-T) Antibody Concentration Equal to or Above 0.1 International Units Per Millilitre (IU/mL).

    Anti-tetanus toxoid antibody concentration cut-off value assessed was ≥ 0.1 IU/mL

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  30. Anti-T Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).

    Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)

  31. Anti-diphtheria Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in IU/mL.

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  32. Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

    Antibody concentrations are expressed as geometric mean concentrations (GMCs) in milli-International Units per millilitre (mIU/mL).

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  33. Anti-poliovirus Types 1, 2, 3 Antibody Titres

    Titres are expressed as geometric mean titres (GMTs)

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  34. Number of Seroprotected Subjects for Anti-diphtheria Antibodies

    Seroprotection status is defined as anti-diphtheria antibody concentrations ≥ 0.1 IU/mL

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  35. Number of Seroprotected Subjects for Anti-hepatitis B Antibodies

    Seroprotection status is defined as anti-HBs antibody concentrations ≥ 10 mIU/mL

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  36. Number of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3 Antibodies

    Seroprotection status is defined as anti-polio 1, 2 and 3 antibody titres ≥ 1:8

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  37. Number of Subjects With Vaccine Response to PT, FHA and PRN

    Vaccine response rates are defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.

    Time frame: One month after the third dose (at study Month 3 - primary phase)

  38. Number of Subjects With Solicited Local Symptoms

    Solicited local symptoms assessed were pain, redness and swelling.

    Time frame: During the 8-day (Day 0-7) follow-up period (during the primary phase)

  39. Number of Subjects With Solicited General Symptoms

    Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).

    Time frame: During the 8-day (Day 0-7) follow-up period (during the primary phase)

  40. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During the 31-day (Day 0-30) follow-up period (during the primary phase)

  41. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

    Time frame: Over the full course of the primary phase (up to study Month 3 - primary phase)

  42. Number of Subjects With Solicited Local Symptoms

    Solicited local symptoms assessed were pain, redness and swelling.

    Time frame: During the 8-day (Day 0-7) follow-up period (during the booster phase)

  43. Number of Subjects With Solicited General Symptoms

    Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).

    Time frame: During the 8-day (Day 0-7) follow-up period (during the booster phase)

  44. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During the 31-day (Day 0-30) follow-up period (during the booster phase)

  45. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

    Time frame: Over the full course of the booster phase (up to study Month 1 - booster phase)

07

Results

Posted Jul 23, 2012

Participant flow

Primary Phase
Participant flow — Primary Phase
MilestoneMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Started7877787877
Completed7673777776
Not completed24111
Withdrew: Lost to follow-up11011
Withdrew: Protocol violation01000
Withdrew: Adverse event11000
Withdrew: Withdrawal by subject01000
Withdrew: Other00100
Booster Phase
Participant flow — Booster Phase
MilestoneMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Started4742444444
Completed4542444443
Not completed20001
Withdrew: Lost to follow-up20001

Outcome measures

PrimaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

Time frame:
One month after dose 3 (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).6666697357
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

rSBA-MenC antibody titre cut-off value assessed was ≥1:8

Time frame:
One month after dose 3 (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:87067717471
PrimaryNumber of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

rSBA-MenY antibody titre cut-off value assessed was ≥1:8

Time frame:
One month after dose 3 (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:86764701614
PrimaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

Time frame:
One month after the booster vaccination (at study Month 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).3939394039
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

rSBA-MenC antibody titre cut-off value assessed was ≥1:8

Time frame:
One month after the booster vaccination (at study Month 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:84039424139
PrimaryNumber of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

rSBA-MenY antibody titre cut-off value assessed was ≥1:8

Time frame:
One month after the booster vaccination (at study Month 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:84039421314
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

rSBA-MenC antibody titre cut-off value assessed was ≥1:8

Time frame:
Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:846463
SecondaryNumber of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

rSBA-MenY antibody titre cut-off value assessed was ≥1:8

Time frame:
Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:81110161017
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

Time frame:
Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).138893
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)

Time frame:
Prior to the booster vaccination (at study Month 0 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).2628273211
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8

rSBA-MenC antibody titre cut-off value assessed was ≥1:8

Time frame:
Prior to the booster vaccination (at study Month 0 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:83838383936
SecondaryNumber of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8

rSBA-MenY antibody titre cut-off value assessed was ≥1:8

Time frame:
Prior to the booster vaccination (at study Month 0 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:83531361115
SecondaryrSBA-MenC Antibody Titres

Titres are expressed as geometric mean titres (GMTs)

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · Titers
rSBA-MenC Antibody Titres
TitersMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-MenC [Month 0] (N=69,64,70,73,71)4.7 (3.9 to 5.7)4.8 (4.1 to 5.6)4.6 (4.0 to 5.4)4.7 (4.0 to 5.7)4.5 (3.9 to 5.2)
rSBA-MenC [Month 3] (N=70,67,71,74,71)1005.8 (773.5 to 1308.0)1029.8 (799.7 to 1326.0)906.9 (691.3 to 1189.8)871.0 (677.3 to 1120.0)3557.6 (2978.8 to 4248.8)
SecondaryrSBA-MenY Antibody Titres

Titres are expressed as geometric mean titres (GMTs)

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · Titers
rSBA-MenY Antibody Titres
TitersMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-MenY [Month 0] (N=70,63,71,73,71)5.9 (4.7 to 7.5)5.9 (4.6 to 7.6)7.4 (5.6 to 9.9)5.9 (4.6 to 7.4)7.7 (5.7 to 10.3)
rSBA-MenY [Month 3] (N=69,66,71,74,71)470.7 (351.1 to 631.2)437.1 (322.0 to 593.4)635.3 (501.5 to 804.8)9.3 (6.3 to 13.7)7.5 (5.4 to 10.4)
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PRP >= 0.15 µg/mL [Mth 0] (N=69,63,71,73,71)5142505050
Anti-PRP >= 0.15 µg/mL [Mth 3] (N=67,67,70,74,71)6767707471
SecondaryAnti-PRP Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PRP [Month 0] (N=69,63,71,73,71)0.289 (0.217 to 0.385)0.243 (0.185 to 0.318)0.255 (0.197 to 0.331)0.243 (0.184 to 0.319)0.217 (0.177 to 0.267)
Anti-PRP [Month 3] (N=67,67,70,74,71)9.014 (7.248 to 11.209)9.485 (7.721 to 11.651)8.075 (6.532 to 9.982)10.435 (8.487 to 12.830)2.595 (1.965 to 3.428)
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSC [Month 0] (N=69,63,71,74,71)7127710
Anti-PSC [Month 3] (N=69,66,70,74,71)6966707471
SecondaryNumber of Subjects With Anti-polysaccharide Y (Anti-PSY) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

Anti-PSY antibody concentration cut-off value assessed was ≥0.30 µg/mL

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polysaccharide Y (Anti-PSY) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSY [Month 0] (N=69,64,71,73,71)76121512
Anti-PSY [Month 3] (N=69,66,70,74,71)69667064
SecondaryAnti-PSC Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · µg/mL
Anti-PSC Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSC [Month 0] (N=69,63,71,74,71)0.18 (0.16 to 0.20)0.20 (0.17 to 0.24)0.18 (0.16 to 0.21)0.18 (0.15 to 0.22)0.18 (0.16 to 0.21)
Anti-PSC [Month 3] (N=69,66,70,74,71)21.70 (18.36 to 25.65)27.26 (23.26 to 31.95)19.02 (16.49 to 21.93)21.08 (18.24 to 24.35)38.49 (33.64 to 44.05)
SecondaryAnti-PSY Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · µg/mL
Anti-PSY Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSY [Month 0] (N=69,64,71,73,71)0.19 (0.16 to 0.23)0.18 (0.15 to 0.20)0.20 (0.17 to 0.25)0.22 (0.18 to 0.27)0.20 (0.17 to 0.23)
Anti-PSY [Month 3] (N=69,66,70,74,71)26.86 (22.86 to 31.56)37.02 (31.84 to 43.04)23.57 (19.94 to 27.86)0.19 (0.15 to 0.25)0.17 (0.15 to 0.19)
SecondaryAnti-tetanus Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Geometric mean · IU/mL
Anti-tetanus Antibody Concentrations
IU/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-tetanus [Month 0] (N=69,63,71,73,71)0.433 (0.320 to 0.586)0.485 (0.373 to 0.630)0.523 (0.388 to 0.705)0.436 (0.323 to 0.589)0.379 (0.285 to 0.503)
Anti-tetanus [Month 3] (N=68,67,70,74,71)3.057 (2.629 to 3.554)3.254 (2.879 to 3.677)2.972 (2.591 to 3.409)3.151 (2.726 to 3.641)1.656 (1.394 to 1.967)
SecondaryAnti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN), Anti-pertussis Toxoid (Anti-PT) Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in Enzyme-Linked Immunosorbent Assay (ELISA) Units per millilitre.

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Least squares mean · EL.U/mL
Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN), Anti-pertussis Toxoid (Anti-PT) Antibody Concentrations
EL.U/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PT [Month 0] (N=67,62,68,70,69)3.4 (2.9 to 4.0)3.1 (2.7 to 3.5)3.7 (3.0 to 4.6)3.3 (2.8 to 4.0)3.1 (2.7 to 3.5)
Anti-PT [Month 3] (N=67,63,69,74,69)53.9 (46.3 to 62.7)52.9 (45.3 to 61.8)50.8 (44.1 to 58.5)55.4 (48.1 to 63.7)41.3 (35.1 to 48.5)
Anti-FHA [Month 0] (N=69,63,69,72,70)6.5 (5.2 to 8.1)6.0 (4.8 to 7.5)7.3 (5.7 to 9.3)9.9 (7.8 to 12.6)7.0 (5.6 to 8.7)
Anti-FHA [Month 3] (N=67,63,69,74,71)83.7 (72.9 to 96.0)91.5 (78.7 to 106.3)89.3 (78.4 to 101.6)92.4 (79.8 to 106.9)74.0 (64.9 to 84.5)
Anti-PRN [Month 0] (N=68,62,71,72,70)6.3 (4.9 to 8.2)4.5 (3.6 to 5.7)5.5 (4.5 to 6.8)6.4 (4.9 to 8.3)6.5 (5.0 to 8.4)
Anti-PRN [Month 3] (N=68,67,70,74,71)94.2 (77.6 to 114.5)97.1 (79.8 to 118.2)96.2 (80.2 to 115.5)99.1 (79.0 to 124.3)80.2 (66.1 to 97.2)
SecondaryNumber of Seroprotected Subjects for Anti-tetanus Antibodies

Seroprotection status is defined as anti-tetanus toxoid antibody concentration ≥ 0.1 International Units per millilitre (IU/mL)

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Number · Subjects
Number of Seroprotected Subjects for Anti-tetanus Antibodies
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-tetanus [Month 0] (N=69,63,71,73,71)5857606361
Anti-tetanus [Month 3] (N=68,67,70,74,71)6867707471
SecondaryNumber of Subjects With Anti-FHA, Anti-PRN and Anti-PT Antibody Concentration Equal to or Above 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units Per Millilitre (EL.U/mL)

Anti-FHA, anti-PRN and anti-PT antibody concentration cut-off value assessed was ≥ 5 ELISA units per millilitre.

Time frame:
Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-FHA, Anti-PRN and Anti-PT Antibody Concentration Equal to or Above 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units Per Millilitre (EL.U/mL)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PT [Month 0] (N=67,62,68,70,69)151118129
Anti-PT [Month 3] (N=67,63,69,74,69)6763697469
Anti-FHA [Month 0] (N=69,63,69,72,70)4237425545
Anti-FHA [Month 3] (N=67,63,69,74,71)6763697471
Anti-PRN [Month 0] (N=68,62,71,72,70)3625373737
Anti-PRN [Month 3] (N=68,67,70,74,71)6867707471
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).

Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PRP >= 0.15 µg/mL Month 0 (N=41,39,42,42,36)3938424236
Anti-PRP >= 0.15 µg/mL Month 1 (N=39,39,39,40,39)3939394039
SecondaryAnti-PRP Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PRP [Month 0] (N=41,39,42,42,36)1.306 (0.947 to 1.801)1.591 (1.185 to 2.135)1.414 (1.068 to 1.871)1.764 (1.301 to 2.391)0.607 (0.459 to 0.802)
Anti-PRP [Month 1] (N=39,39,39,40,39)36.280 (27.856 to 47.252)32.930 (22.797 to 47.567)34.107 (24.902 to 46.715)47.742 (34.631 to 65.817)24.345 (17.445 to 33.974)
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:128

rSBA-MenC antibody titre cut-off value assessed was ≥1:128

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:128
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-Menc [Month 0] (N=42,39,41,41,38)2524222726
rSBA-Menc [Month 1] (N=40,39,42,41,39)4036424039
SecondaryNumber of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:128

rSBA-MenY antibody titre cut-off value assessed was ≥1:128

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:128
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-MenY [Month 0] (N=41,39,42,42,37)24182367
rSBA-MenY [Month 1] (N=40,39,42,40,39)403942610
SecondaryrSBA-MenC Antibody Titres

Titres are expressed as geometric mean titres (GMTs)

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · Titers
rSBA-MenC Antibody Titres
TitersMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-MenC [Month 0] (N=42,39,41,41,38)128.0 (74.9 to 218.5)144.2 (92.8 to 224.1)125.8 (81.0 to 195.3)150.6 (96.7 to 234.5)195.5 (122.4 to 312.2)
rSBA-MenC [Month 1] (N=40,39,42,41,39)4762.6 (3427.5 to 6617.7)2897.7 (1793.1 to 4682.7)2626.4 (1893.9 to 3642.3)3226.2 (2294.7 to 4535.8)11819.3 (8458.6 to 16515.2)
SecondaryrSBA-MenY Antibody Titres

Titres are expressed as geometric mean titres (GMTs)

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · Titres
rSBA-MenY Antibody Titres
TitresMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
rSBA-MenY [Month 0] (N=41,39,42,42,37)97.2 (58.4 to 161.8)64.0 (37.6 to 108.9)100.9 (62.3 to 163.5)11.0 (6.3 to 19.1)16.1 (8.8 to 29.5)
rSBA-MenY [Month 1] (N=40,39,42,40,39)1708.1 (1313.3 to 2221.4)1313.8 (1004.4 to 1718.6)1566.0 (1172.8 to 2091.1)11.7 (6.8 to 20.2)16.5 (8.7 to 31.3)
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)

Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSC [Month 0] (N=38,38,40,40,38)3838404038
Anti-PSC [Month 1] (N=33,33,39,37,39)3333393739
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 2.0 Microgram Per Millilitre (µg/mL)

Anti-PSC antibody concentration cut-off value assessed was ≥2.0 µg/mL

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 2.0 Microgram Per Millilitre (µg/mL)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSC [Month 0] (N=38,38,40,40,38)2430282627
Anti-PSC [Month 1] (N=33,33,39,37,39)3333393739
SecondaryAnti-PSC Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · µg/mL
Anti-PSC Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSC [Month 0] (N=38,38,40,40,38)2.57 (1.88 to 3.51)3.23 (2.55 to 4.08)2.53 (2.06 to 3.12)3.08 (2.33 to 4.08)3.17 (2.46 to 4.08)
Anti-PSC [Month 1] (N=33,33,39,37,39)32.04 (22.99 to 44.65)28.00 (19.40 to 40.42)19.75 (15.23 to 25.60)27.71 (22.23 to 34.54)64.41 (50.72 to 81.79)
SecondaryAnti-PSY Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · µg/mL
Anti-PSY Antibody Concentrations
µg/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PSY [Month 0] (N=39,39,42,42,38)3.72 (2.76 to 5.03)5.25 (3.95 to 6.96)3.96 (3.02 to 5.19)0.16 (0.14 to 0.19)NA (NA to NA)
Anti-PSY [Month 1] (N=42,39,41,40,38)26.15 (17.80 to 38.42)35.90 (25.33 to 50.88)32.18 (25.26 to 40.99)0.17 (0.13 to 0.21)NA (NA to NA)
SecondaryNumber of Subjects With Anti-tetanus Toxoid (Anti-T) Antibody Concentration Equal to or Above 0.1 International Units Per Millilitre (IU/mL).

Anti-tetanus toxoid antibody concentration cut-off value assessed was ≥ 0.1 IU/mL

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects With Anti-tetanus Toxoid (Anti-T) Antibody Concentration Equal to or Above 0.1 International Units Per Millilitre (IU/mL).
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-tetanus [Month 0] (N=41,39,42,42,38)4139424237
Anti-tetanus [Month 1] (N=39,39,39,40,39)3939394039
SecondaryAnti-T Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).

Time frame:
Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Reported as:
Geometric mean · IU/mL
Anti-T Antibody Concentrations
IU/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-tetanus [Month 0] (N=41,39,42,42,38)0.836 (0.655 to 1.067)0.986 (0.810 to 1.202)0.894 (0.748 to 1.069)0.839 (0.693 to 1.016)0.322 (0.257 to 0.402)
Anti-tetanus [Month 1] (N=39,39,39,40,39)12.609 (10.769 to 14.762)10.175 (8.269 to 12.520)9.893 (8.255 to 11.856)11.674 (9.538 to 14.288)5.474 (4.331 to 6.918)
SecondaryAnti-diphtheria Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in IU/mL.

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Geometric mean · IU/mL
Anti-diphtheria Antibody Concentrations
IU/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-diphtheria Antibody Concentrations1.016 (0.796 to 1.297)0.927 (0.759 to 1.132)0.980 (0.788 to 1.219)1.012 (0.827 to 1.238)1.904 (1.606 to 2.258)
SecondaryAnti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

Antibody concentrations are expressed as geometric mean concentrations (GMCs) in milli-International Units per millilitre (mIU/mL).

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
mIU/mLMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations377.9 (261.7 to 545.8)397.0 (271.5 to 580.4)408.9 (305.9 to 546.6)520.5 (374.1 to 724.3)287.3 (194.3 to 424.7)
SecondaryAnti-poliovirus Types 1, 2, 3 Antibody Titres

Titres are expressed as geometric mean titres (GMTs)

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Geometric mean · Titers
Anti-poliovirus Types 1, 2, 3 Antibody Titres
TitersMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-poliovirus type 1 (N=57,55,56,61,56)275.5 (206.9 to 366.8)242.0 (181.2 to 323.4)216.8 (162.6 to 288.9)305.2 (229.2 to 406.4)282.6 (204.4 to 390.7)
Anti-poliovirus type 2 (N=55,55,58,61,56)155.8 (110.4 to 220.0)149.9 (108.3 to 207.7)133.7 (95.5 to 187.2)123.1 (86.3 to 175.6)171.3 (123.2 to 238.1)
Anti-poliovirus type 3 (N=57,55,58,61,56)649.0 (492.3 to 855.7)577.2 (418.7 to 795.8)451.7 (320.9 to 635.9)603.6 (452.7 to 804.6)505.7 (375.5 to 681.0)
SecondaryNumber of Seroprotected Subjects for Anti-diphtheria Antibodies

Seroprotection status is defined as anti-diphtheria antibody concentrations ≥ 0.1 IU/mL

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Seroprotected Subjects for Anti-diphtheria Antibodies
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Seroprotected Subjects for Anti-diphtheria Antibodies6664697469
SecondaryNumber of Seroprotected Subjects for Anti-hepatitis B Antibodies

Seroprotection status is defined as anti-HBs antibody concentrations ≥ 10 mIU/mL

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Seroprotected Subjects for Anti-hepatitis B Antibodies
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Seroprotected Subjects for Anti-hepatitis B Antibodies6060667061
SecondaryNumber of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3 Antibodies

Seroprotection status is defined as anti-polio 1, 2 and 3 antibody titres ≥ 1:8

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3 Antibodies
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-poliovirus type 1 (N=57,55,56,61,56)5755566155
Anti-poliovirus type 2 (N=55,55,58,61,56)5555585956
Anti-poliovirus type 3 (N=57,55,58,61,56)5755586156
SecondaryNumber of Subjects With Vaccine Response to PT, FHA and PRN

Vaccine response rates are defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.

Time frame:
One month after the third dose (at study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects With Vaccine Response to PT, FHA and PRN
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Anti-PT (N=64,58,66,70,68)6358646668
Anti-FHA (N=66,59,67,72,70)6558656870
Anti-PRN (N=66,62,70,72,70)6159686365
SecondaryNumber of Subjects With Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling.

Time frame:
During the 8-day (Day 0-7) follow-up period (during the primary phase)
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Symptoms
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Pain2120221919
Redness3538503246
Swelling3135302735
SecondaryNumber of Subjects With Solicited General Symptoms

Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).

Time frame:
During the 8-day (Day 0-7) follow-up period (during the primary phase)
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Drowsiness3953433746
Irritability4442514744
Loss of appetite2434293330
Fever (rectal) >= 38.0°C2528262828
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
During the 31-day (Day 0-30) follow-up period (during the primary phase)
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events (AEs)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Unsolicited Adverse Events (AEs)3933353126
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Time frame:
Over the full course of the primary phase (up to study Month 3 - primary phase)
Reported as:
Number · Subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects Reporting Serious Adverse Events (SAEs)01213
SecondaryNumber of Subjects With Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling.

Time frame:
During the 8-day (Day 0-7) follow-up period (during the booster phase)
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Symptoms
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Pain510889
Redness2018221616
Swelling151212910
SecondaryNumber of Subjects With Solicited General Symptoms

Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).

Time frame:
During the 8-day (Day 0-7) follow-up period (during the booster phase)
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Drowsiness1418181718
Irritability1618191417
Loss of appetite1116121014
Fever (rectal) >= 38.0°C1310161816
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
During the 31-day (Day 0-30) follow-up period (during the booster phase)
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events (AEs)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects With Unsolicited Adverse Events (AEs)712131211
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

Time frame:
Over the full course of the booster phase (up to study Month 1 - booster phase)
Reported as:
Number · Subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
SubjectsMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Number of Subjects Reporting Serious Adverse Events (SAEs)11010

Adverse events

Collected over SAEs: Over the full course of the primary and booster phases (up to Month 3 - primary phase and up to Month 1 - booster phase). Unsolicited AEs: During the 31-day (Days 0-30) follow-up period. Solicited AEs: During the 8-day (Days 0-7) follow-up period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Menhibrix F1/Infanrix-penta Group—1/78 (1.3%)70/78 (89.7%)
Menhibrix F2/Infanrix-penta Group—1/77 (1.3%)71/77 (92.2%)
Menhibrix F3/Infanrix-penta Group—2/78 (2.6%)73/78 (93.6%)
Menitorix/Infanrix-penta Group—1/78 (1.3%)71/78 (91%)
Menjugate/Infanrix-hexa Group—3/77 (3.9%)70/77 (90.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
Febrile convulsionNervous system disorders0/471/420/440/440/44
Upper respiratory tract infectionInfections and infestations0/471/420/440/440/44
Otitis mediaInfections and infestations0/470/420/441/440/44
GastroenteritisInfections and infestations1/470/420/440/440/44
ApnoeaRespiratory, thoracic and mediastinal disorders0/780/770/780/781/77
BronchitisInfections and infestations0/780/770/780/781/77
DehydrationMetabolism and nutrition disorders0/780/770/780/781/77
GastroenteritisInfections and infestations0/780/770/780/781/77
Laryngotracheo bronchitisInfections and infestations0/780/770/780/781/77
Urinary tract infectionInfections and infestations0/781/770/780/780/77
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMenhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa Group
DrowsinessGeneral disorders39/7853/7743/7837/7846/77
IrritabilityGeneral disorders44/7842/7751/7847/7844/77
RednessGeneral disorders35/7838/7750/7832/7846/77
RednessGeneral disorders20/4718/4222/4416/4416/44
SwellingGeneral disorders31/7835/7730/7827/7835/77
Loss of appetiteGeneral disorders24/7834/7729/7833/7830/77
IrritabilityGeneral disorders16/4718/4219/4414/4417/44
DrowsinessGeneral disorders14/4718/4218/4417/4418/44
FeverGeneral disorders13/4710/4216/4418/4416/44
Loss of appetiteGeneral disorders11/4716/4212/4410/4414/44

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Menhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa GroupTotal
Mean8.5 ± 1.698.8 ± 1.728.7 ± 1.558.3 ± 1.639.0 ± 1.658.7 ± 1.65
Sex: Female, Male
Sex: Female, Male(Participants)Menhibrix F1/Infanrix-penta GroupMenhibrix F2/Infanrix-penta GroupMenhibrix F3/Infanrix-penta GroupMenitorix/Infanrix-penta GroupMenjugate/Infanrix-hexa GroupTotal
Female3137443340185
Male4740344537203
08

Study locations

26 sites
  • GSK Investigational Site
    Asse, 1730, Belgium
  • GSK Investigational Site
    Drongen, 9031, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Maldegem, 9990, Belgium
  • GSK Investigational Site
    Merelbeke, 9820, Belgium
  • GSK Investigational Site
    Oudenaarde, 9700, Belgium
  • GSK Investigational Site
    Sint-Amandsberg, 9040, Belgium
  • GSK Investigational Site
    Cham, Bayern 93413, Germany
  • GSK Investigational Site
    Kaufering, Bayern 86916, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80939, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Noerdlingen, Bayern 86720, Germany
  • GSK Investigational Site
    Olching, Bayern 82140, Germany
  • GSK Investigational Site
    Niedernhausen, Hessen 65527, Germany
  • GSK Investigational Site
    Detmold, Nordrhein-Westfalen 32756, Germany
  • GSK Investigational Site
    Kirchlengern, Nordrhein-Westfalen 32278, Germany
  • GSK Investigational Site
    Loehne, Nordrhein-Westfalen 32584, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04178, Germany
  • GSK Investigational Site
    Bredstedt, Schleswig-Holstein 25821, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24937, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24943, Germany
  • GSK Investigational Site
    Berlin, 10315, Germany
  • GSK Investigational Site
    Berlin, 12627, Germany
  • GSK Investigational Site
    Berlin, 13355, Germany
  • GSK Investigational Site
    Berlin, 14197, Germany
  • GSK Investigational Site
    Hamburg, 22307, Germany
09

References and documents

Publications

  • Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011 Jul;10(7):941-50. doi: 10.1586/erv.11.90. PubMed 21806393 ↗
  • Habermehl P, Leroux-Roels G, Sanger R, Machler G, Boutriau D. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccin. 2010 Aug;6(8):640-51. doi: 10.4161/hv.6.8.12154. PubMed 20697200 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Dec 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2005
First posted
Aug 11, 2005
Start
Mar 1, 2003
Primary completionActual
Dec 1, 2003
CompletionActual
Dec 16, 2003
Results first posted
Jul 23, 2012
Last update
Aug 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00129116
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 11, 2005
Start date
Mar 1, 2003
Primary completion
Dec 1, 2003
Completion
Dec 16, 2003
Results posted
Jul 23, 2012
Last update
Aug 27, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hib-MenCY-TT vaccine · Pediarix

Start the discussion